Biosimilars are a growing new class of medicines approved by the Food and Drug Administration (FDA) as safe and effective treatments for diseases such as cancer, rheumatoid arthritis, plaque psoriasis and chronic kidney disease. They provide America’s patients with access to lower-cost medicines and the nation’s health care system with substantial savings.

Biosimilars Deliver Access & Savings

- Biosimilars have been used in more than 121 million days of patient therapy in the U.S. and have resulted in almost 10 million additional days of therapy.

- The introduction of a biosimilar pegfilgrastim alone resulted in an increase of more than 1 million patient days of therapy in the U.S.

Patent Thickets, Rebate Traps, Misaligned Reimbursement Incentives Suppress Uptake

Patients in the U.S. are missing out on lower costs and increased access to the safe and effective medicines on which they rely.

The FDA has approved 30 biosimilars to date, but only 20 of these products are commercially available in the United States.

Biosimilars Council urges policymakers in Congress and the Administration to support increased reimbursement for biosimilars, through a temporary increase in the biosimilar add-on payment or a shared savings program, and to support Medicare Part D reform to encourage biosimilar adoption.

Altogether, these proposals would result in lower costs and greater patient access to care.

Learn more at biosimilarcouncil.org/advocacy